抗血管内皮生长因子药物在糖尿病视网膜病变中的应用进展

发布时间：2018-05-02 06:36

本文选题：糖尿病视网膜病变 + 糖尿病性黄斑水肿　；参考：《医学综述》2016年20期

【摘要】：糖尿病视网膜病变(DR)是糖尿病患者严重的微血管并发症,其细胞和分子机制尚不完全清楚。视网膜新生血管的形成是导致DR患者严重视力损害的重要因素之一,而血管内皮生长因子(VEGF)在新生血管形成中起重要作用。目前,抗VEGF药物已广泛用于年龄相关性黄斑变性的治疗,并在向糖尿病性黄斑水肿及增殖性DR等眼部其他血管性疾病治疗方向扩展,它的发明预示着眼科血管性疾病治疗新时代的到来。
[Abstract]:Diabetic retinopathy (DRN) is a severe microvascular complication in diabetic patients, and its cellular and molecular mechanisms are not fully understood. Retinal neovascularization is one of the important factors leading to severe visual impairment in Dr patients, and vascular endothelial growth factor (VEGF) plays an important role in neovascularization. At present, anti- VEGF drugs have been widely used in the treatment of age-related macular degeneration, and have been extended to other vascular diseases such as diabetic macular edema and proliferative Dr. Its invention heralds the arrival of a new era in the treatment of ophthalmic vascular diseases.
【作者单位】：武汉大学人民医院眼科中心;
【分类号】：R774.1;R587.2

【相似文献】